SCHEMBL20258290

SCHEMBL20258290

CC(C)(C)OC(=O)N1C[C@H](NOCc2ccccc2)CC[C@]1(C(=O)O)N1C(=O)CCC1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 1/20 0.36
STS P08842 1/20 0.36
PARP1 P09874 1/20 0.35
KMT2A Q03164 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
KLK7 P49862 1/20 0.35
JAK2 O60674 1/20 0.34
JAK1 P23458 1/20 0.34
GPR119 Q8TDV5 1/20 0.34
YAP1 P46937 2/20 0.34
KDM4E B2RXH2 1/20 0.33
PKM P14618 1/20 0.33
GHSR Q92847 1/20 0.33
KEAP1 Q14145 1/20 0.33
NFE2L2 Q16236 1/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17956503 0.91 USP30 (0.36) USP30STSPARP1KMT2AL3MBTL1
SCHEMBL20258276 0.89 USP30 (0.37) USP30STSPARP1KMT2AL3MBTL1
SCHEMBL18044440 0.89 USP30 (0.37) USP30STSPARP1KMT2AL3MBTL1
SCHEMBL17956400 0.89 USP30 (0.37) USP30STSPARP1KMT2AL3MBTL1
SCHEMBL17956487 0.88 STS (0.35) USP30STSPARP1KMT2AL3MBTL1
SCHEMBL20258282 0.88 STS (0.35) USP30STSPARP1KMT2AL3MBTL1
SCHEMBL17956419 0.88 CTSL (0.33) KMT2AMEN1ALDH1A1
SCHEMBL20258292 0.86 SMN1; SMN2 (0.37) USP30STSKMT2AL3MBTL1JAK2
SCHEMBL17956483 0.81 USP30 (0.38) USP30STSKMT2AL3MBTL1KLK7
SCHEMBL17956450 0.81 ALDH1A1 (0.35) USP30KMT2AL3MBTL1YAP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10000491-B2 Process for producing diazabicyclooctane derivative and intermediate thereof MEIJI SEIKA PHARMA CO., LTD. (JP) 2018-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10000491-B2 Process for producing diazabicyclooctane derivative and intermediate thereof CLCN2, ODC1, KCNN4 USP30 3438/4885STS 3538/4885PARP1 1835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.